<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[162, 169] survival, toxicity, and overall response<br>[284, 285] Toxicity<br>[416, 417] myelosuppression<br></td>
<td width=33%>
[162, 169] survival, toxicity, and overall response<br>[279, 280] hematotoxicity<br>[284, 285] Toxicity<br>[298, 299] leukopenia<br>[307, 309] thrombocytopenia;<br>[313, 314] leukopenia<br>[319, 321] thrombocytopenia.<br>[322, 324] response rate<br>[338, 341] hematological toxicity,<br>[350, 351] leukopenia<br>[372, 373] thrombocytopenia<br>[404, 410] steep dose-response curve,<br>[416, 417] myelosuppression<br>[420, 423] Rates of responses<br></td>
<td width=33%>
[10, 15] untreated advanced breast cancer--<br>[42, 45] significant activity in<br>[47, 55] and some activity in Phase I trials.<br>[68, 69] toxicity<br>[75, 85] formation of an active metabolite, N-acetyl-<br>[162, 180] survival, toxicity, and overall response when limited exposure to Phase II agents precedes standard chemotherapy.<br>[243, 246] visceral crisis.<br>[271, 275] and reduction in dose<br>[279, 280] hematotoxicity<br>[284, 291] Toxicity was primarily hematological and bimodal:<br>[298, 299] leukopenia<br>[307, 309] thrombocytopenia;<br>[312, 314] no leukopenia<br>[319, 321] thrombocytopenia.<br>[322, 324] response rate<br>[338, 341] hematological toxicity,<br>[350, 351] leukopenia<br>[368, 373] response if patients had thrombocytopenia<br>[404, 420] steep dose-response curve, based on the significant correlation between myelosuppression and response.<br>[420, 425] Rates of responses in patients<br>[432, 434] hematotoxicity)<br></td>
</tr>
